Clinical Trial Update: A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study) [Phase 3]

View source ↗

Summary

Phase 3 extension study assessing andexanet alfa to reverse anticoagulation from direct and indirect oral anticoagulants in acute major bleeding, completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Bleeding

Drugs mentioned

• Andexanet alfa (andexanet alfa)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Bleeding | Phase 3 | Status: COMPLETED | Results posted: 2022-02-16